Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on Betamethasone Sodium Phosphate and Drug Combination for Pregnant Women with Preterm Premature Rupture of Membranes

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on a condition known as preterm premature rupture of membranes (pPROM) in pregnancy. This condition occurs when the amniotic sac, which holds the baby and amniotic fluid, breaks earlier than expected, specifically before 37 weeks of pregnancy. The study aims to explore a personalized treatment approach to safely prolong pregnancy, improve outcomes for both the mother and the newborn, and reduce unnecessary use of antibiotics.

The trial will evaluate the effectiveness of a tailored treatment plan that includes specific antibiotics and steroids. The antibiotics being studied include gentamicin, benzylpenicillin, demeclocycline hydrochloride, and ampicillin combined with a beta-lactamase inhibitor. The steroid used in the study is dexamethasone. Additionally, magnesium sulfate is included for its neuroprotective properties. The treatment plan is based on the levels of a substance called IL-6 in the amniotic fluid, which is obtained through a procedure known as amniocentesis. This approach is compared to the standard treatment to see if it can help extend the pregnancy duration.

Participants in the study will receive either the tailored treatment or a standard treatment, which may include a placebo. The study will monitor how long the pregnancy lasts after the membranes rupture, as well as any short-term health effects on the mother and baby. The goal is to determine if the personalized treatment can effectively prolong pregnancy and improve health outcomes. The study will also look at the presence of certain infections and the microbiome, which is the collection of microorganisms in the body, in both the mother and the newborn.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, you will be asked to sign a consent form. This form confirms your understanding and agreement to participate in the trial.

  2. Step 2

    Initial assessment

    An initial assessment will be conducted to confirm your eligibility. This includes verifying your age, pregnancy weeks, and the condition of preterm premature rupture of membranes (pPROM).

  3. Step 3

    Amniocentesis procedure

    A procedure called amniocentesis will be performed to collect a small sample of amniotic fluid. This is done to measure the level of a substance called IL-6, which helps tailor your treatment.

  4. Step 4

    Treatment plan

    Based on the IL-6 value, a personalized treatment plan will be created. This may include antibiotics and steroids to help prolong your pregnancy and improve outcomes for you and your baby.

  5. Step 5

    Medication administration

    You may receive medications such as dexamethasone and gentamicin through injections or infusions. The specific medications, dosage, and frequency will be determined by your treatment plan.

  6. Step 6

    Monitoring and follow-up

    Regular monitoring will be conducted to track your health and the progress of your pregnancy. This includes checking for any signs of infection or other complications.

  7. Step 7

    Completion of the trial

    The trial will conclude after the birth of your baby. The primary goal is to achieve a latency period of more than 7 days from the rupture of membranes to delivery.

Who can join the trial?

6 criteria

  • Must be 18 years or older.
  • Must have a condition called preterm premature rupture of membranes (pPROM), confirmed by a test called Amnisure or by a doctor's examination. This means the water around the baby breaks earlier than expected.
  • Must be between 22 weeks and 33 weeks and 6 days of pregnancy.
  • Must be pregnant with one baby (not twins or more).
  • Must have signed a consent form agreeing to participate in the study.
  • Must have had a completely uncomplicated pregnancy until the occurrence of pPROM.

Who cannot join the trial?

5 criteria

  • Patients who are not pregnant cannot participate.
  • Men cannot participate in the study.
  • Patients who do not have a condition called preterm premature rupture of membranes cannot participate. This is when the water breaks early in pregnancy.
  • Patients who are not within the specified age range for the study cannot participate.
  • Patients who are part of a vulnerable population, such as those who cannot give consent, are not included.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Antibiotic Therapy

    is used in this trial to help prevent or treat infections in patients who have experienced a premature rupture of membranes during pregnancy. The goal is to reduce the risk of infection for both the mother and the baby, which can be a concern when the protective amniotic sac breaks early. By using antibiotics, the trial aims to prolong the pregnancy safely and improve outcomes for both the mother and the newborn.

  • Steroid Therapy

    is another treatment used in this trial. Steroids are given to help the baby's lungs mature more quickly if there is a risk of preterm birth. This is important because the lungs are one of the last organs to fully develop in a baby. By speeding up lung development, steroids can help reduce the risk of breathing problems in the newborn if they are born prematurely. The trial is investigating whether using steroids based on specific test results can improve outcomes for both the mother and the baby.

What is already known about the treatment

Tailored Antibiotic and Steroid Therapy – This medication is administered through a procedure called amniocentesis, where a sample of amniotic fluid is taken to measure the IL-6 value, which helps in deciding the specific treatment. Currently, this approach is being studied in clinical trials to see if it can help prolong pregnancy in cases of preterm premature rupture of membranes, a condition where the water breaks early in pregnancy. The main goal is to improve outcomes for both the mother and baby while reducing the need for antibiotics. The therapy works by targeting inflammation at the molecular level, which is indicated by the IL-6 marker, and is classified under anti-inflammatory and antibiotic treatments.

Investigated diseases

Preterm Premature Rupture of Membranes – This condition occurs when the amniotic sac breaks before 37 weeks of pregnancy and before the onset of labor. It leads to the leakage of amniotic fluid, which can increase the risk of infection for both the mother and the baby. The rupture can result in complications such as chorioamnionitis, an infection of the amniotic fluid and membranes, and funisitis, an inflammation of the umbilical cord. The progression of this condition can lead to preterm birth, which may affect the baby's development and health. The time between the rupture and delivery is referred to as the latency period, which can vary in length. Monitoring and management are crucial to minimize risks and prolong pregnancy when possible.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-520237-77-00Protocol codeTAILORED-PROMEstimated enrolment138 patientsSponsorVseobecna Fakultni Nemocnice V Praze

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.